{"entity":{"id":"gc-cell","kind":"company","name":"GC Cell","aka":["GC Cell Corporation","Green Cross Cell","GC Cell Corp."],"tldr":"GC Cell is a South Korean cell therapy company whose autologous cytokine-induced killer cell product Immuncell-LC has been approved in Korea since 2007 as adjuvant treatment after liver cancer surgery.","summary":"GC Cell, part of the GC (Green Cross) group and listed in Korea, was formed in 2021 from Green Cross Cell and Green Cross LabCell. Its longest-standing product is Immuncell-LC, autologous cytokine-induced killer cells given after resection of hepatocellular carcinoma, approved in South Korea in 2007 and supported by a phase 3 trial showing longer recurrence-free survival; the company also develops CAR-T and NK cell therapies. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.gccell.com"},{"label":"ClinicalTrials.gov: trials led by GC Cell","url":"https://clinicaltrials.gov/search?lead=GC%20Cell"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc"],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Yongin","country":"KR","companyType":"cell-therapy","website":"https://www.gccell.com","stage":"public","investors":[],"funding":[]},"route":"/companies/gc-cell/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}]}}